NCT02977832View on ClinicalTrials.gov

Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Benign Prostatic Hypertrophy With Outflow ObstructionBenign Prostatic Hyperplasia
Interventions
DIETARY_SUPPLEMENT

Odyliresin

Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)

DRUG

Alfuzosin

10Mg Oral Tablet, Extended Release

Trial Locations (1)

27100

Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT02977832 - Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter